Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBloomsbury Regulatory News (BMY)

Share Price Information for Bloomsbury (BMY)

Share Price is delayed by 15 minutes
Get Live Data
655.00    -1.00 (-0.15%)
Bid:
654.00
Ask:
656.00
Spread: 2.00 (0.306%)
Market Cap: £533.14m
BMY Live PriceLast checked at - London Stock Exchange

Intraday Bloomsbury Share Chart

Acquisition

6 Jan 2009 08:41

RNS Number : 1619L
Bloomsbury Publishing PLC
06 January 2009
 



 

Bloomsbury Publishing Plc

("Bloomsbury")

Bloomsbury acquires Arden Shakespeare

Bloomsbury Publishing Plc is pleased to announce the acquisition of Arden Shakespeare from Cengage Learning. This transaction is not material to Bloomsbury.

  Arden Shakespeare is the most academically rigorous Shakespeare series in print, and the best-known English literature brand worldwide. Originally created by the British publishing firm of Methuen in the late nineteenth century, and edited by a distinguished collection of scholars, the series took 25 years to complete from the launch of the first title, Edward Dowden's Hamlet, in 1899. In 1995 the Third Series of The Arden Shakespeare was launched. Now published under the imprint Arden Shakespeare, under the General Editorship of Richard Proudfoot, Ann Thompson, David Scott Kastan and Henry Woudhuysen, the Arden Shakespeare Third Series is nearing completion. Each new volume supersedes the corresponding Second Series text, being meticulously edited from the original sources by a contemporary scholar.

Arden Shakespeare will retain its internationally recognised name and become part of the Methuen Drama imprint (acquired in 2006 by A&C Black which is a wholly owned subsidiary of Bloomsbury). The acquisition will make Methuen Drama Europe's largest performing arts list, which includes work by Bertolt Brecht, Oscar Wilde, Bernard Shaw and Arthur Miller as well as contemporary playwrights such as Michael Frayn and Willy Russell, Methuen Student editions and the New Mermaids critical editions.

'I am delighted that the Arden Shakespeare series is returning to MethuenArden is a highly prestigious addition to our performing arts publishing and fits perfectly with our strategy of acquiring high quality perennial publishing lists which have significant potential for digital exploitation. We look forward to working with the Arden General Editors Richard Proudfoot, Ann Thompson, David Scott Kastan and Henry Woudhuysen to grow and strengthen this important list' says A&C Black Managing Director, Jill Coleman.

Jill Jones, CEO Cengage Learning EMEA said, 'The Arden Shakespeare is an excellent fit for Bloomsbury: we wish A&C Black, all volume editors, authors and General Editors from the Arden Shakespeare success for the future'.

www.methuendrama.com

-ends-

For further enquiries:

Bloomsbury Publishing PLC

Jill Coleman, Bloomsbury Publishing Plc care of Bell Pottinger

Bell Pottinger Corporate & Financial

Ben Woodford / Rosanne Perry +44 (0)20 7861 3232

Notes to Editors

About Bloomsbury Publishing Plc 

(www.bloomsbury.com and www.bloomsbury-ir.co.uk)

Bloomsbury Publishing is one of the world's leading independentpublicly quoted publishing houses with a reputation for a high quality management team and a highly valuable portfolio of intellectual properties including the Encarta World English Dictionary, JK Rowling's Harry Potter, Margaret Atwood, John Irving, David Guterson and Ben Schott. Other databases include Who's Who, Whitaker's AlmanackReed's Nautical Almanac, Black's Medical Dictionary, the Macmillan English Dictionary for Advanced Learners of EnglishBusiness: The Ultimate Resource and RSPB Handbook of British Birds. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQUNOWRKKRARRR
Date   Source Headline
16th Feb 20079:13 amRNSHolding(s) in Company
15th Feb 20075:26 pmRNSResults Notice
13th Feb 200711:57 amRNSHolding(s) in Company
13th Feb 200711:39 amRNSHolding(s) in Company
1st Feb 200712:01 pmRNSDeathly Hallows
23rd Jan 20075:41 pmRNSHolding(s) in Company
22nd Jan 20079:31 amRNSTotal Voting Rights
10th Jan 20071:38 pmRNSHolding(s) in Company
8th Jan 20075:52 pmRNSHolding(s) in Company
20th Dec 20064:16 pmRNSTotal Voting Rights
11th Dec 20066:01 pmRNSTrading Update
22nd Nov 20062:56 pmRNSHolding(s) in Company
17th Nov 20064:02 pmRNSBlocklisting Interim Review
31st Oct 20064:35 pmRNSDirector/PDMR Shareholding
27th Oct 200610:45 amRNSDirector/PDMR Shareholding
4th Oct 20064:39 pmRNSHolding(s) in Company
19th Sep 20067:02 amRNSInterim Results
19th Jul 200611:46 amRNSDirector/PDMR Shareholding
5th Jul 200610:53 amRNSHolding(s) in Company
5th Jul 200610:37 amRNSHolding(s) in Company
4th Jul 20063:24 pmRNSDirector/PDMR Shareholding
29th Jun 20063:41 pmRNSResult of Meeting
29th Jun 20067:02 amRNSAGM Statement
28th Jun 20064:10 pmRNSDirector/PDMR Shareholding
15th Jun 20065:32 pmRNSHolding(s) in Company
5th Jun 20066:04 pmRNSNotice of AGM
2nd Jun 20068:14 amRNSAnalyst Seminar
25th May 20067:00 amRNSAcquisition
23rd May 20069:15 amRNSHolding(s) in Company
17th May 20065:13 pmRNSBlocklisting Interim Review
17th May 20064:53 pmRNSHolding(s) in Company
21st Apr 20064:42 pmRNSHolding(s) in Company
13th Apr 20065:07 pmRNSDirector/PDMR Shareholding
4th Apr 20067:02 amRNSFinal Results
8th Feb 20065:23 pmRNSHolding(s) in Company
6th Feb 20064:28 pmRNSDirector/PDMR Shareholding
3rd Feb 20069:56 amRNSHolding(s) in Company
12th Jan 20065:23 pmRNSHolding(s) in Company
11th Jan 20067:00 amRNSPre-Close Trading Update
30th Nov 20053:40 pmRNSDirector/PDMR Shareholding
24th Nov 20054:03 pmRNSAppointment
17th Nov 20055:45 pmRNSBlocklisting Interim Review
10th Nov 20053:18 pmRNSHolding(s) in Company
7th Nov 20054:25 pmRNSDirector/PDMR Shareholding
27th Oct 20054:39 pmRNSDirector/PDMR Shareholding
3rd Oct 20053:57 pmRNSDirector/PDMR Shareholding
28th Sep 200512:43 pmRNSResult of Meeting
26th Sep 200512:00 pmRNSAdditional Listing
23rd Sep 200510:37 amRNSDirector/PDMR Shareholding
13th Sep 20057:03 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.